-
Vox Sanguinis 1976A method for detecting traces of beta-propiolactone, which was previously described by Schmitz-Masse, has been modified and adapted to the analysis of protein solutions....
A method for detecting traces of beta-propiolactone, which was previously described by Schmitz-Masse, has been modified and adapted to the analysis of protein solutions. Using this method, the rate of hydrolysis of beta-propiolactone (beta-P1) was examined and beta-P1 sterilized commercial products were analyzed for possible residual nonhydrolyzed beta-P1.
Topics: Blood Proteins; Chromatography, Gas; Humans; Hydrolysis; Immunoglobulins; Lactones; Propiolactone; Solutions; Sterilization
PubMed: 969391
DOI: 10.1159/000467314 -
Biotechnology (Reading, Mass.) 1991Plasma protein solutions such as albumin and intramuscular immune globulin have long histories of viral safety. Coagulation factor concentrates as traditionally... (Review)
Review
Plasma protein solutions such as albumin and intramuscular immune globulin have long histories of viral safety. Coagulation factor concentrates as traditionally manufactured frequently transmitted HBV, HCV, and HIV. Indeed, it is probable that every vial of concentrate contained infectious HCV. Modern coagulation factor concentrates have a greatly improved safety record arising, principally, from the implementation of virucidal procedures. It is interesting to note that the same methods that failed to substantially reduce NANBHV transmission in clinical studies are those that were found to inactivate less than 10(4) ID50 of HIV, HBV, and/or HCV in preclinical studies (Table 17-5). Implementation even of these methods nearly eliminated the transmission of HIV by coagulation factor concentrates. A summary of the results of the most successful procedures is given in Table 17-10. The results show 0/564 patients had evidence of HIV transmission, 6/151 patients had evidence of HBV transmission, and 2/301 patients had evidence of HCV transmission. As compared with those procedures described in Table 17-5, the greater kill of HIV, HBV, and NANBHV demonstrated preclinically, and the improved clinical results, are most notable. The data, examined in terms of units transfused, are presented in Figure 17-1. Since the average adult hemophiliac in the United States receives 80,000 units of clotting factor per year, the best of the concentrates show safety over the equivalent of at least 10-human-years of treatment. Are the best of today's coagulation factor concentrates safe from the transmission of HBV, NANBHV (including HCV), and HIV. Given the limited number of patients eligible for clinical studies, and the length, difficulty, and expense of such studies, the best answer comes from a knowledge of the initial virus load coupled with information regarding virus removal, serendipitous inactivation, and intentional sterilization. A recently completed analysis of these factors (Horowitz 1990) indicates that the best of the modern coagulation factor concentrates are likely to be as safe as albumin (Figure 17-2).
Topics: Blood; Blood Proteins; Detergents; Freeze Drying; HIV Infections; Hepatitis, Viral, Human; Hot Temperature; Humans; Organophosphates; Propiolactone; Risk; Safety; Transfusion Reaction; Ultraviolet Rays; Virus Diseases; Viruses
PubMed: 1786476
DOI: 10.1016/b978-0-7506-9120-8.50022-6 -
Biochemical Pharmacology Jul 1965
Topics: Chemical Phenomena; Chemistry; Chromatography, Paper; Guanine; Lactones; Nucleosides; Spectrophotometry; Ultraviolet Rays
PubMed: 5854740
DOI: 10.1016/0006-2952(65)90040-7 -
Proceedings of the Society For... Feb 1956
Topics: Animals; Chickens; Meat; Newcastle Disease; Newcastle disease virus; Propiolactone; Propionates; Viruses
PubMed: 13297779
DOI: 10.3181/00379727-91-22240 -
Infection 1987The inactivation of HIV in human plasma and plasma derivatives by combined treatment with beta-propiolactone and UV-irradiation was investigated. beta-propiolactone...
The inactivation of HIV in human plasma and plasma derivatives by combined treatment with beta-propiolactone and UV-irradiation was investigated. beta-propiolactone inactivated greater than or equal to 3.5 log10 and UV greater than or equal to 2.8 log10 HIV in plasma and beta-propiolactone greater than or equal to 3.5 log10 in cryoprecipitate and UV irradiation greater than or equal to 4.5 log10 in factor VIII concentrate.
Topics: Drug Contamination; Factor VIII; Fibrinogen; Fibronectins; HIV; Humans; Plasma; Propiolactone; Ultraviolet Rays
PubMed: 3121517
DOI: 10.1007/BF01647745 -
British Journal of Cancer Dec 1961
Topics: Carcinogens; Humans; Lactones; Propiolactone
PubMed: 13910215
DOI: 10.1038/bjc.1961.91 -
Vox Sanguinis 1984Non-A/Non-B type 1 hepatitis virus may be recognized because it induces characteristic tubular ultrastructures in the hepatocyte cytoplasm of chimpanzees. 3 chimps...
Non-A/Non-B type 1 hepatitis virus may be recognized because it induces characteristic tubular ultrastructures in the hepatocyte cytoplasm of chimpanzees. 3 chimps received 0.1 ml of a chimp serum containing more than 100 chimp infecting units of non-A/non-B type 1 hepatitis virus after it had been treated with beta-propiolactone with or without combined ultraviolet irradiation. All of the chimps escaped infection throughout the observation period of 23 weeks. The treatment of the serum with beta-propiolactone at the mildest condition employed (0.05%, 4 degrees C, 20 min) was still effective in inactivating the virus. The susceptibility of the chimps was ascertained by the subsequent challenge with 0.1 ml of the untreated serum which invariably induced non-A/non-B type 1 hepatitis in them. On the basis of these results, beta-propiolactone was extremely efficacious for the cold sterilization of non-A/non-B type 1 hepatitis virus.
Topics: Animals; Hepatitis C; Hepatitis Viruses; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; Lactones; Male; Microtubules; Pan troglodytes; Propiolactone; Transfusion Reaction; Ultraviolet Rays; Virus Activation
PubMed: 6422638
DOI: 10.1111/j.1423-0410.1984.tb00057.x -
Journal of Virology Oct 1974Polyoma virus was inactivated by treatment with beta-propiolactone. T-antigen production, polyoma-RNA synthesis, induction of host DNA synthesis (measured by...
Polyoma virus was inactivated by treatment with beta-propiolactone. T-antigen production, polyoma-RNA synthesis, induction of host DNA synthesis (measured by incorporation of labeled thymidine into the cell culture), and in vitro transforming ability were inactivated to a similar degree by various beta-propiolactone concentrations (0.25% beta-propiolactone reduced these functions approximately 96%), whereas plaque-forming ability and the ability of the virus to replicate its DNA and to synthesize capsid antigen were inactivated by a given concentration of beta-propiolactone to a much greater degree (0.25% beta-propiolactone led to a reduction of plaque-forming ability of over 8 logs). The significance of these data and their relationship to previously published experiments are discussed.
Topics: Animals; Antigens, Viral; Autoradiography; Cell Transformation, Neoplastic; Culture Techniques; DNA, Viral; Heterocyclic Compounds; Histocompatibility Antigens; Kidney; Lactones; Mice; Polyomavirus; Propionates; RNA, Viral; Thymidine; Tritium; Uridine; Viral Proteins
PubMed: 4370764
DOI: 10.1128/JVI.14.4.840-845.1974 -
Viruses Jun 2020In late 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, the capital of the Chinese province Hubei. Since then,...
In late 2019, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, the capital of the Chinese province Hubei. Since then, SARS-CoV-2 has been responsible for a worldwide pandemic resulting in over 4 million infections and over 250,000 deaths. The pandemic has instigated widespread research related to SARS-CoV-2 and the disease that it causes, COVID-19. Research into this new virus will be facilitated by the availability of clearly described and effective procedures that enable the propagation and quantification of infectious virus. As work with the virus is recommended to be performed at biosafety level 3, validated methods to effectively inactivate the virus to enable the safe study of RNA, DNA, and protein from infected cells are also needed. Here, we report methods used to grow SARS-CoV-2 in multiple cell lines and to measure virus infectivity by plaque assay using either agarose or microcrystalline cellulose as an overlay as well as a SARS-CoV-2 specific focus forming assay. We also demonstrate effective inactivation by TRIzol, 10% neutral buffered formalin, beta propiolactone, and heat.
Topics: Animals; Betacoronavirus; COVID-19; Cellulose; Chlorocebus aethiops; Coronavirus Infections; Culture Media; Formaldehyde; Guanidines; HEK293 Cells; Humans; Pandemics; Phenols; Pneumonia, Viral; Propiolactone; SARS-CoV-2; Sepharose; Vero Cells; Viral Plaque Assay; Virus Inactivation
PubMed: 32517266
DOI: 10.3390/v12060622 -
The Journal of Infectious Diseases 1956
Topics: Bacteria; Propiolactone; Propionates; Spores, Bacterial
PubMed: 13376916
DOI: 10.1093/infdis/99.3.212